epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Similar documents
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY

CHEMOTHERAPY

Fig. 1 Chemical structure of DL-8280

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle


CHEMOTHERAPY


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


VOL.42 S-1



日本化学療法学会雑誌第61巻第6号


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin



Table1MIC of BAY o 9867 against standard strains


CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

VOL. 34 S-2 CHEMOTH8RAPY 913

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin



CHEMOTHERAPY MAY. 1988

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

日本化学療法学会雑誌第58巻第4号


日本化学療法学会雑誌第53巻第S-3号

04-c-„FŒ{›xŒ¾-4.01

VOL. 43 NO. 4

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

988 CHEMOTHERAPY NOV. 1971

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Fig. 1 Chemical structure of norfioxacin (AM-715)


- 1 -


Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det



THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

Transcription:

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Table 3. Overall clinical efficacy of cefozopran in complicated UTI after 5 day's treatment (0.5 g or 1g ~ 2/day) Table 4. Overall clinical efficacy of cefozopran classified by the type of UTI after 5 days treatment (0.5g or 1g ~ 2/day)

274 CHEMOTHERAPY DEC. 1993 Table 5 Bacteriological response to cefozopran in complicated UTI after 5 day's treatment (0.5 g or 1g ~ 2/day) Table 6. Relation between MIC and Bacteriological response after 5 day's cafozopran treatment No. of strains eradicated/no. of strains isolated

1) Miyake A, Yoshimura Y, Yamaoka M, Nishimura T, Hashimoto N, Imada A: Studies on condensed -heterocyclic azolium cephalosporins IV* Syn - thesis and antibacterial activity of 7ƒÀ[2- (5- amino- 1, 2,4 -thiadiazol-3 - yl) -2 (Z) -alkoxyiminoacetamido] - 3 - (condensedheterocyclic azolium) methyl cephalosporins including SCE- 2787. J Antibiot 45 (5) : 709-720, 1992 2) Nakao M, Noji Y, Iwahi T, Yamazaki T: Antibacterial properties of SCE-2787, a new cephem antibiotic. J Antimicrob Chemother 29 :509-518, 1992 3) Iwahi T, Okonogi K, Yamazaki T, Shiki S, Kondo M, Miyake A, Imada A : In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a Broad Antibacterial Spectrum. Antimicrob Agent Chemother 36 (7) : 1358-1366, 1992

Fundamental and clinical study of cefozopran in urinary tract infections Noriaki Tanaka, Takaoki Hirose, Naoto Mikuma and Yoshiaki Kumamoto Department of Urology, School of Medicine, Sapporo Medical University 291 Nishi 16, Minami 1-jo, chuo-ku Sappro 060, Japan Cefozopran (CZOP), a newly developed cephem antibiotic, was assessed fundamentally and clinically. The fundamental study included determination of minimum inhibitory concentrations (MICs) of CZOP, ceftazidime (CAZ), cefuzonam (CZON) and flomoxef (FMOX) against 4 species of gram-positive cocci and 7 species of gram-negative bacilli, which had been clinically isolated and stored in our laboratory, using the MIC 2000 system (105CFU inoculated per ml). The MIC90 of CZOP was 0.78 Đg/ml for methicillinsensitive Staphylococcus aureus, 3.13 Đg/ml for methicillin-resistant Staphylococcus aureus, 0.78 Đg/ml for Staphylococcus epidermidis, 12.5 Đg/ml for Enterococcus faecalis, 100 Đg/ml or above for Enterococcus faecium 0.05 Đg/ml for Escherichia coli, 0.1 Đg/ml for Klebsiella pneumoniae, 0.2 Đg/ml for Proteus mirabilis, 0.78 Đg/ ml for indole-positive Proteus spp., 6.25 Đg/ml each Enterobacter spp. and Serratia marcescens, and 50 Đg/ml for Pseudomonas aeruginosa. In comparison with other antibiotics, CZOP had distinctly greater antimicrobial activity against all cocci except E. faecium. Against bacilli, such as E. coli Enterobacter spp. and S. marcescens, CZOP exerted antimicrobial activity 1 to 5 times more potent than that of any of the other antibiotics compared. The antimicrobial activity of CZOP against cocci was definitely greater than that of the others, and its activity against bacilli was equal of greater than those of the others. In the clinical study, CZOP was administered to 17 patients with complicated urinary tract infections (11 with cystitis and 1 with pyelonephritis), and the clinical effects and side effects were investigated. CZOP was administered at a dose of 0.5-1.0 g once or twice a day for 5 days. The general clinical effects were evaluated according to the criteria proposed by the Japanese UTI Committee for drug efficacy evaluation in 13 of the 17 patients. The rate of general efficacy was 69.2 %. The bacteria elimination rate was 80.0 % of 20 strains. In particular, all 4 strains of E. faecalis and all 3 strains of P. aeruginosa were eliminated. No side effects considered likely to be attributable to the drug were observed. One patient showed a GPT elevation as an abnormal finding on the clinical tests.

2026 © docsplayer.net プライバシー | 利用規約 | フィードバック